"As you all know, pharma players and investors all

"As you all know, pharma players and investors all operate off of capital budgets. AMBS had very gray targets and areas of uncertainty in 2014. Most of these issues have been tied up. Even when a deal is sweet, the capital isn't always easy to come by without the BOD seeing significant value. I would suspect that Eltropazine, Lympro and variations of MANF will all have offers dropped on the table within two months based on capital timing, will Gerald accept? The core difference in partnerships is now freeing the capital in advance for 2015 to make the deal based on facts and attributes that simply weren't there. Gerald is holding off on RS for a reason. Once the next indication meets designation, I would suspect they will have very strong valuation on the MANF platform from real analysts. Type 1 Diabetes is their next target, it can get ODD fastest and will lead to Type 2. I know I will hear from someone, "stick to the science", this is the science. This is my life, it's not just the research, it's the timing of execution and watching things launch. I admit, I really thought Provenge and HSP were going to be great platforms, they weren't so much as expected. It was fun to watch them both go through incubation, MANF is different, significantly. You saw what Denderon did, imagine MANF having the ability to go to market with 20x the power, imagine it without the liabilities of a Provenge. Agenus will be interesting to watch. Your uplist can now happen, ODD and Lympro just crossed the valuation needed for the next exchange, they already have the capital. Expect news on this in weeks."-- WATSONHELPER